Literature DB >> 3839626

Elevated serum calcitriol concentrations do not fall in response to hyperphosphatemia in familial tumoral calcinosis.

R Steinherz, R W Chesney, B Eisenstein, A Metzker, H F DeLuca, M Phelps.   

Abstract

Five affected members in two branches of a Druze Arab kindred presented with calcified deposits in or about the hips and knees, indicating the diagnosis of tumoral calcinosis. Serum vitamin D metabolite concentrations, immunoreactive parathyroid hormone, and the tubular reabsorption of phosphate were measured in three affected siblings, as well as in their parents and an unaffected sibling. Normocalcemia and hyperphosphatemia with an elevated tubular maximum for phosphate per glomerular filtration rate were found in the affected patients. Levels of serum immunoreactive parathyroid hormone were normal, and the calcitriol value (1,25-dihydroxyvitamin D) was normal or elevated in the three affected patients. A trial of a low-phosphorus diet and oral aluminum hydroxide gel did not lower serum phosphate levels or improve the calcified deposits. These findings suggest that serum calcitriol values do not decline in response to hyperphosphatemia in tumoral calcinosis and that hyperphosphatemia with elevated tubular reabsorption of phosphate is a constant feature of this disorder because the kidney fails to excrete the increased filtered load of phosphate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839626     DOI: 10.1001/archpedi.1985.02140100078036

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  12 in total

1.  Tumoral calcinosis revisited--common and uncommon features. Report of ten cases and review.

Authors:  A Metzker; B Eisenstein; J Oren; R Samuel
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

2.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.

Authors:  Yaacov Frishberg; Orit Topaz; Reuven Bergman; Doron Behar; Drora Fisher; Derek Gordon; Gabriele Richard; Eli Sprecher
Journal:  J Mol Med (Berl)       Date:  2004-12-15       Impact factor: 4.599

3.  Vitamin D metabolism in tumoral calcinosis.

Authors:  R Steinherz
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

4.  Tumoral calcium pyrophosphate deposition disease.

Authors:  H A Sissons; G C Steiner; F Bonar; M May; Z S Rosenberg; H Samuels; D Present
Journal:  Skeletal Radiol       Date:  1989       Impact factor: 2.199

Review 5.  Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.

Authors:  Lisal J Folsom; Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

6.  Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.

Authors:  Eli Sprecher
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

Review 7.  Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.

Authors:  Ilana Chefetz; Eli Sprecher
Journal:  Biochim Biophys Acta       Date:  2008-10-25

8.  GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.

Authors:  Ilana Chefetz; Kimitoshi Kohno; Hiroto Izumi; Jouni Uitto; Gabriele Richard; Eli Sprecher
Journal:  Biochim Biophys Acta       Date:  2008-10-11

9.  Hyperphosphatemic familial tumoral calcinosis: odontostomatologic management and pathological features.

Authors:  Gianfranco Favia; Maria Grazia Lacaita; Luisa Limongelli; Angela Tempesta; Nicola Laforgia; Angela Pia Cazzolla; Eugenio Maiorano
Journal:  Am J Case Rep       Date:  2014-12-24

Review 10.  Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.

Authors:  Silje Rafaelsen; Stefan Johansson; Helge Ræder; Robert Bjerknes
Journal:  BMC Genet       Date:  2014-09-24       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.